Ipamorelin raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-08-21. Anything still debated is marked as such rather than presented as settled.
Structural features distinguish the molecule from earlier secretagogues. An alpha-aminoisobutyric acid residue near the N-terminus and a D-naphthylalanine substitution increase receptor affinity, while C-terminal amidation improves resistance to exopeptidases. These modifications are associated with reduced stimulation of appetite and of the hypothalamic-pituitary-adrenal axis compared with hexarelin or growth hormone releasing peptide-6. Whether the same profile applies at every dose level studied is a matter of ongoing investigation rather than settled consensus.
Ipamorelin is a synthetic pentapeptide that acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. Its sequence incorporates non-natural residues, which slows enzymatic breakdown relative to short native peptides. In laboratory and early clinical work the compound is described as a selective growth hormone secretagogue because it raises growth hormone with comparatively little effect on other pituitary outputs. The degree to which that selectivity holds across species and dosing regimens remains an open question in the published literature.
Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Reported for the free peptide |
| Molecular mass | 711.85 Da | Monoisotopic value |
| Residue motif | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | Non-natural residues at positions one and three |
| Primary target | GHSR-1a | Ghrelin receptor, G protein coupled |
| Reported plasma half-life | About two hours | Values vary with assay and subject group |
In the scientific literature, ipamorelin appears mainly in preclinical studies, receptor binding assays, and reviews of growth hormone secretagogues. Authors often discuss its selectivity profile alongside limitations such as small sample sizes, short study durations, and differences between species. Some papers examine pharmacokinetics and clearance, but human data are limited and not sufficient to define general clinical effects. Regulatory discussion treats the compound as an investigational or research substance rather than an approved therapy in most jurisdictions. Open questions include oral bioavailability, long-term endocrine effects, and whether selectivity observed in animals persists in humans.
Research peptides such as ipamorelin are commonly supplied as lyophilized powder and characterized by analytical certificates. Reversed-phase high-performance liquid chromatography is used to estimate purity by ultraviolet absorbance, while mass spectrometry confirms molecular identity and detects sequence-related impurities. Counterion content, water content, and residual synthesis reagents can affect the reported mass balance. A certificate of analysis may list a purity percentage, but that number depends on the analytical method and the definition of impurity peaks. Independent verification is often recommended because research supply chains vary in quality control practices.
Storage recommendations for ipamorelin usually focus on temperature, moisture, and light. Lyophilized powder is typically held at or below minus twenty degrees Celsius in a desiccated container protected from light. Reconstituted solutions are often aliquoted and stored at minus eighty degrees Celsius to reduce repeated freeze-thaw cycles, which can promote aggregation or degradation. The optimal buffer and pH depend on the specific assay, and no single condition applies to every experimental context. Peptide stability should be assessed with time-point measurements rather than assumed from general handling rules.
冻干状态下的肽通常比溶液状态更稳定，常规做法是维持 -20 °C 或更低温度、保持干燥并避开强光。复溶后的降解主要来自水解、氧化与脱酰胺，速率受 pH、缓冲液种类、离子强度与温度共同影响，碱性条件一般会加快这些反应。反复冻融会造成聚集与容器吸附损失，分装保存能降低该风险。容器材质与金属离子也可能参与氧化过程，需与操作条件一并考虑。
对 ipamorelin 的常规表征以反相高效液相色谱测定纯度，检测波长多设为 214 nm，因为肽键在该波长有较强吸收。身份确认通常借助电喷雾电离质谱或串联质谱，将实测分子量与理论值逐项比对。序列层面可用肽图分析或氨基酸分析进一步验证。这些手段组合起来，可以分别覆盖纯度、身份与序列三个不同层次的信息。
杂质谱一般包含缺失序列片段、差向异构体、氧化产物以及残留溶剂或反离子，其中组氨酸与芳香残基的氧化常被重点关注。反相色谱中这类杂质往往紧邻主峰洗脱，因此方法需要足够的分离度并经过系统适用性验证。纯度百分比的解读依赖于检测波长与梯度条件，不同实验室公布的数字不宜直接横向比较。参考标准品有助于跨批次对照，但其自身赋值同样需要可追溯来源。
Analytical confirmation relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry for identity and purity assessment. Mass spectrometry distinguishes the intact molecule from truncation products and from oxidation or deamidation variants that share similar chromatographic retention. Immunoassays appear in some biological studies but can cross-react with related peptides, so they are weaker tools for identity work. Reported purity figures depend heavily on the gradient, detector, and integration method used, which complicates direct comparison between laboratories.
Research quantities of ipamorelin are typically distributed as a white to off-white lyophilized powder. The solid dissolves readily in water and in aqueous buffers, and stock solutions are commonly prepared in sterile water or a mildly acidic diluent. Adsorption to plastic and glass surfaces can reduce the concentration of very dilute solutions, so containers and transfer steps deserve attention when accurate concentrations matter. Reconstituted material is generally used promptly rather than held for extended periods.
Storage recommendations for the dry solid center on low temperature and low moisture, most often -20 °C in a sealed, desiccated container protected from light. Solutions are less stable than the powder and are usually kept cold and used within a short window. Freeze-thaw cycling is a recognized source of loss, and aliquoting before freezing is a standard precaution. These practices derive from general peptide handling principles rather than from a single published stability trial, so exact shelf lives should be treated as approximate.
从用途定位看，ipamorelin 目前主要以研究用肽的身份被讨论，未见主要药品监管机构将其批准为治疗药物。市售材料通常标注仅供研究使用，不得用于人体或诊断程序。文献中它常与生长激素促分泌素、GHS-R1a 激动剂、胃饥饿素拟似物等表述并列出现。既有研究的样本量普遍偏小，因此对其效应强度与一致性的描述应保持谨慎。
Ipamorelin 是一种合成五肽，序列为 Aib-His-D-2-Nal-D-Phe-Lys-NH2，分子式 C38H49N9O5，游离碱分子量约 711.85 g/mol。它属于生长激素促分泌素（GHS）家族，作用靶点是胃饥饿素受体 GHS-R1a。该化合物由诺和诺德的研究团队在二十世纪九十年代末报道，设计目标是提高对生长激素释放的选择性。C 端酰胺化与 N 端 Aib 残基是两个用于抵抗肽酶降解的结构特征。
在 GHS 家族中，早期肽类如 GHRP-6 与 GHRP-2 会同时促进生长激素、皮质醇与催乳素的释放，并明显增加食欲。Ipamorelin 在动物与早期人体研究中表现出对生长激素释放的相对选择性，对上述其他激素的影响较小。这种差异通常归因于受体结合模式与下游信号偏向的不同，而完整的分子解释仍有待补充。需要区分的是，选择性是研究观察中的相对程度，并非绝对界限。
Tyrannosaurus () is a genus of large theropod dinosaur. The type species Tyrannosaurus rex (rex meaning 'king' in Latin), often shortened to T. rex or colloquially T-Rex, is one of the best represented theropods. It lived throughout what is now western North America, on what was then an island continent known as Laramidia. Tyrannosaurus had a much wider range than other tyrannosaurids. Fossils are found in a variety of geological formations which have been dated to the late Maastrichtian age of the late Cretaceous period, 69 to 66 million years ago, with isolated specimens possibly indicating an earlier origin in the middle Campanian age. It was one of the last known members of the tyrannosaurids and among the last non-avian dinosaurs to exist before the Cretaceous–Paleogene extinction event. Like other tyrannosaurids, Tyrannosaurus was a bipedal carnivore with a massive skull balanced by a long, heavy tail. Relative to its large and powerful hind limbs, the forelimbs of Tyrannosaurus were short but unusually powerful for their size, and they had two clawed digits. The most complete specimen measures 12.3–12.4 m (40–41 ft) in length, but according to most modern estimates, Tyrannosaurus could have exceeded sizes of 13 m (43 ft) in length, 3.7–4 m (12–13 ft) in hip height, and 8.8 t (8.7 long tons; 9.7 short tons) in mass. Although some other theropods might have rivaled or exceeded Tyrannosaurus in size, it is still among the largest known land predators, with its estimated bite force being the largest among all terrestrial animals.
=== Mutations === Cystinosis is presented in patients with a range of CTNS mutations; as of 2017, over 100 have been identified. The most common mutation is a 57,257 base pair deletion commonly referred to as the 57 kb deletion. This was formally known as the 65 kb deletion; a misnomer originating from early incorrect estimates. Other reported mutations include other deletions, missense mutations, and in-frame deletions and insertions. The type and extent of mutation determines the type and severity of cystinosis in the carrier. This is a result of the degree of transport inhibition caused by the misfolding of cystinosin. For example, mild cystinosis is typically associated with mutations that do not affect the amino acids in the transmembrane domains of cystinosin. In contrast, infantile nephropathic cystinosis, the most severe form of the disease, is most commonly associated with a total loss of activity. Gene deletion resulting in the absence of either of the sorting motifs results in the delocalization of cystinosin to the cellular plasma membrane.
== Discovery == In the year 1975, timoprazole was found to inhibit acid secretion irrespective of stimulus, extracellular or intracellular. Studies on timoprazole revealed enlargement of the thyroid gland due to inhibition of iodine uptake as well as atrophy of the thymus gland. A literature search showed that some substituted mercapto-benzimidazoles had no effect on iodine uptake and introduction of such substituents into timoprazole resulted in an elimination of the toxic effects, without reducing the antisecretory effect. A derivative of timoprazole, omeprazole, was discovered in 1979, and was the first of a new class of drug that control acid secretion in the stomach, a proton pump inhibitor (PPI). Addition of 5-methoxy-substitution to the benzimidazole moiety of omeprazole was also made and gave the compound much more stability at neutral pH. In 1980, an Investigational New Drug (IND) application was filed and omeprazole was taken into Phase III human trials in 1982. A new approach for the treatment of acid-related diseases was introduced, and omeprazole was quickly shown to be clinically superior to the histamine H2 receptor antagonists, and was launched in 1988 as Losec in Europe, and in 1990 as Prilosec in the United States. In 1996, Losec became the world's biggest ever selling pharmaceutical, and by 2004 over 800 million patients had been treated with the drug worldwide.
==== Korea ==== The earliest soy sauce brewing in Korea seems to have begun in the era of the Three Kingdoms. Jangdoks used for soy sauce brewing are found in the mural paintings of Anak Tomb No. 3 from the 4th century Goguryeo. In Samguk sagi, a historical record of the Three Kingdoms era, it is written that ganjang (soy sauce) and doenjang (soybean paste), along with meju (soybean block) and jeotgal (salted seafood), were prepared for the wedding ceremony of the King Sinmun in February 683. Sikhwaji, a section from Goryeosa (History of Goryeo), recorded that ganjang and doenjang were included in the relief supplies in 1018, after a Khitan invasion, and in 1052, when a famine occurred. Joseon texts such as Guhwangchwaryo and Jeungbo sallim gyeongje contain the detailed procedures on how to brew good quality ganjang and doenjang. Gyuhap chongseo explains how to pick a date for brewing, what to forbear, and how to keep and preserve ganjang and doenjang.
President Harry S. Truman began covertly authorizing direct financial assistance to the French, and on June 27, 1950, after the outbreak of the Korean War, announced publicly that the U.S. was doing so. On June 30, 1950, the first U.S. supplies for Indochina were delivered. In September, Truman sent the Military Assistance Advisory Group (MAAG) to Indochina to assist the French. Later, in 1954, U.S. President Dwight D. Eisenhower explained the escalation risk, introducing what he referred to as the "domino principle", which eventually became the concept of domino theory. After the Moch–Marshall meeting of September 23, 1950, in Washington, United States, started to support the French Union effort politically, logistically and financially. Officially, US involvement did not include use of armed force. As the situation at Dien Bien Phu deteriorated in 1954, France requested more support from the United States, including equipment and direct intervention. For instance, on April 4 French Prime Minister Joseph Laniel and Foreign Minister Georges Bidault conveyed to U.S. Ambassador C. Douglas Dillon that "immediate armed intervention of US carrier aircraft at DienBien Phu is now necessary to save the situation". The United States discussed with allies multiple options, including the use of nuclear weapons. A key concern in the planning was the response of China. While the planning continued, the United States moved an aircraft-carrier task-force, which included the carriers Boxer and Essex, into the South China Sea between the Philippines and Indochina.
Sources: en.wikipedia.org
=== 5th generation cephalosporins === Currently there are only two drugs in this category, ceftobiprole and ceftaroline. These new drugs are also the only β-lactam antibiotics that are effective against methicillin-resistant-Staphylococcus-aureus (MRSA). Ceftobiprole is a pyrrolidinone-3-ylidenemethyl cephem. The C-3 side chain was specifically designed to have a strong binding affinity to PBP2a and PBP2x. PBP2a is known to give staphylococci resistance to other β-lactam drugs and PBPx does the same for pneumococci. Ceftobiprole also has an aminothiazoyl-hydroxyimino side chain at the C-7 position which is known to give good resistance to β-lactamase from S. aureus. Together these active groups make ceftobiprole bactericidal to MRSA. Ceftobiprole has poor water solubility and is therefore administered intravenously as an ester prodrug called ceftobiprole medocaril. It is rapidly broken down into active ceftobiprole by plasma esterases. Ceftaroline was developed from the fourth generation cephalosporin cefozopran. It retains the alkoxyimino group at position C-7 from earlier generations so it is fairly stable in the presence of many β-lactamases. Since MRSA and penicillin-resistant Streptococcus pneumoniae have resistance dedicated to new types of PBP, PBP2a and PBP2x respectively, both ceftaroline and ceftobiprole have C-3 side chains specially engineered to bind these new PBP. In the case of ceftaroline this side chain contains a 2-thioazolythio spacer linkage optimised for its anti-MRSA activity.
Because sites of protein-protein interaction have often been found to be flanked by prolines, the presence of the two prolines in this ‘finger’ of the structure indicates a possible interaction site. A short polypeptide of eight amino acid residues, containing this sequence, was indeed found to block the L-type calcium channels, though with a lesser activity. These interacting amino acids are also found in two other L-type calcium channel blocking proteins, C10S2C2 and S4C8. Although both of these toxins are members of the three-fingered family, the three-fingered structure is probably not a requirement for channel blocking: other snake toxins, including dendrotoxin, have similar effects on various channels, but do not show the three-fingered structure.
Stephen H. White was an American Biophysicist, academic, and author. He was a Professor Emeritus of Physiology and Biophysics at the University of California, Irvine School of Medicine. White published over 350 papers, was cited over 30,000 times, and had a Google Scholar H-index of 84. He focused his research on structure and folding of membrane proteins, with particular attention on protein structure prediction, peptide–bilayer interactions, cell membrane biophysics, structure of membranes and lipid bilayers, and antimicrobial peptides. He was awarded the 2014 Carl Brändén Award for his contributions to the field of membrane protein folding. He authored several book chapters and two books entitled, Membrane Protein Structure: Experimental Approaches and Cell Boundaries: How Membranes and Their Proteins Work. White was a Fellow of the American Association for the Advancement of Science, Neutron Scattering Society of America, and Biophysical Society, where he also served as President (1996-1997). He served on numerous advisory boards of several professional organizations, including NIH, NSF, Department of Energy, and European Science Foundation.
== Implementation == The Carter Center, who was appointed as the independent observer of the agreement's implementations in 2017, stated that 22% of the accords' provisions were put into effect by 2017, and by 2020, that number had only increased to 23%. While the Malian Army was dispatched to Kidal as per the terms of the agreement, the troops never actually patrolled the city. Similarly, CMA fighters were sent to Gao under similar provisions. Part of the reason for the lack of implementation was the need for more willingness by the signatories to honor it. A March 2020 survey showed slightly over eighty percent of Malian civilians had little to no knowledge of the peace agreement. The CMA continued to exercise de facto control over the Kidal region, which the Malian government tolerated as Malian government control of the region would force the government to enact constitutional reforms upending the status quo.
==== Equipment ==== As mentioned above, only standard laboratory equipment is required for the use of agarose beads in immunoprecipitation applications, while high-power magnets are required for magnetic bead-based IP reactions. While the magnetic capture equipment may be cost-prohibitive, the rapid completion of immunoprecipitations using magnetic beads may be a financially beneficial approach when grants are due, because a 30-minute protocol with magnetic beads compared to overnight incubation at 4 °C with agarose beads may result in more data generated in a shorter length of time.
Sources: en.wikipedia.org
=== Distribution ratio === In solvent extraction, a distribution ratio (D) is often quoted as a measure of how well-extracted a species is. The distribution ratio is a measure of the total concentration of a solute in the organic phase divided by its concentration in the aqueous phase. The partition or distribution coefficient (Kd) is the ration of solute concentration in each layer upon reaching equilibrium. This distinction between D and Kd is important. The partition coefficient is a thermodynamic equilibrium constant and has a fixed value for the solute’s partitioning between the two phases. The distribution ratio’s value, however, changes with solution conditions if the relative amounts of A and B change. If we know the solute’s equilibrium reactions within each phase and between the two phases, we can derive an algebraic relationship between Kd and D. The partition coefficient and the distribution ratio are identical if the solute has only one chemical form in each phase; however, if the solute exists in more than one chemical form in either phase, then Kd and D usually have different values. Depending on the system, the distribution ratio can be a function of temperature, the concentration of chemical species in the system, and a large number of other parameters. Note that D is related to the Gibbs Free Energy (ΔG) of the extraction process. In solvent extraction, two immiscible liquids are shaken together. The more polar solutes dissolve preferentially in the more polar solvent, and the less polar solutes in the less polar solvent.
Narrated by Martin Jarvis 7 August Turbo: Qualifying Boost, Paul Ray and electronic engineer Steve Taylor, who designed the engine management unit, at Cosworth; each year in Formula 1, the permitted fuel was reduced - for 1986, it was 195 litres; the EEC-IV electronic fuel injection system, an EPROM design; the Lola THL2 is tested at Boreham Circuit in Essex on 21 February 1986, with Patrick Tambay; Geoff Goddard, of Cosworth, who designed the overall engine; automotive engineer Neil Oatley; aerodynamicist Ross Brawn at Cranfield Institute of Technology; 4 March 1986 at Donington Park in Leicestershire; the Haas Lola team, and Cosworth development engineer Martin Walters; the Lotus 98T, of Team Lotus, with its Renault engine; the wastegate of a turbocharger compressor; the 1986 San Marino Grand Prix in northern Italy on 27 April 1986; the Chernobyl disaster had taken place the day before; Paul Ray notices that the exhaust has cracked near the turbocharger; Narrated by Martin Jarvis, produced by Patrick Uden, made by Uden Associates 14 August Prisoner of Consciousness, Sir Jonathan Miller looked at his research into human memory, and 48-year-old BBC musician Clive Wearing, who could not remember more than 10 seconds; Miller had made The Body in Question for the BBC in 1978, with much of the future Equinox team. Directed by John Dollar, produced by Patrick Uden, and made by Uden Associates 21 August A Short History of the Future: The City.
At this point, it was eagerly anticipated that such pharmacometabolomics approaches could be applied to personalized human medicine. Since this publication in 2006, the Pharmacometabolomics Research Network led by Duke University researchers and that included partnerships between centers of excellence in metabolomics, pharmacogenomics and informatics (over sixteen academic centers funded by NIGMS) has been able to illustrate for the first time the power of the pharmacometabolomics approach in informing about treatment outcomes in large clinical studies and with use of drugs that include antidepressants, statins, antihypertensives, antiplatelet therapies and antipsychotics. Totally new concepts emerged from these studies on use of pharmacometabolomics as a tool that can bring a paradigm shift in the field of pharmacology. It illustrated how pharmacometabolomics can enable a Quantitative and Systems Pharmacology approach. Pharmacometabolomics has been applied for the treatment of numerous human diseases, such as schizophrenia, diabetes, neural disease, depression and cancer.
=== Cost === The total project cost, including the land acquisition cost, is around ₹55,000 crore (equivalent to ₹640 billion or US$6.6 billion in 2026). It is among the country's longest greenfield road projects.
The Patrol Ration Pac (PRP) is a shelf-stable product that provides an efficient, flexible and nutritionally robust feeding method. The PRP is designed to cover activities when you have access to other food sources during the day and is ideal to replace a single meal or provide snack options. The PRP provides approximately one-third of the energy and nutrient requirements of most military personnel during moderate, prolonged-intensity physical activity, in a temperate environment. Therefore, it is desirable that all of the food in the pack is eaten. Menus A, B and C contain main meals that can be heated using a flameless ration heater along with other ready to eat foods and a beverage powder. Menu D provides ready to eat snack foods and no beverage powder.
Sources: en.wikipedia.org
Both molecules activate the same receptor, GHSR-1a, but they share little sequence identity. Ghrelin is a 28-amino-acid hormone carrying a distinctive acyl modification, whereas ipamorelin is a short synthetic peptide. The shared target explains overlapping endocrine effects, while the different structures account for differences in metabolic stability and receptor selectivity.
Early animal and human studies reported growth hormone release at levels that produced small changes in cortisol, prolactin and adrenocorticotropic hormone. That contrast with older secretagogues gave rise to the selectivity label. The observation is consistent across several reports but rests on a limited number of small studies.
Plasma peptidases cleave the molecule into smaller fragments, and reported half-lives in human studies are on the order of a couple of hours. The identity and activity of individual breakdown products have not been fully mapped. Questions about tissue-level clearance remain open.
The peptide is Aib-His-D-2-Nal-D-Phe-Lys-NH2. Two of its residues are non-natural, which slows enzymatic degradation. The C-terminal amide is common among bioactive peptides.